Logo image of ORP.PA

EMEIS SA (ORP.PA) Stock Fundamental Analysis

EPA:ORP - Euronext Paris - Matif - FR001400NLM4 - Common Stock - Currency: EUR

12.465  +0.15 (+1.24%)

Fundamental Rating

4

ORP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 30 industry peers in the Health Care Providers & Services industry. While ORP is still in line with the averages on profitability rating, there are concerns on its financial health. ORP is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year ORP was profitable.
ORP had a positive operating cash flow in the past year.
ORP had positive earnings in 4 of the past 5 years.
ORP had a positive operating cash flow in each of the past 5 years.
ORP.PA Yearly Net Income VS EBIT VS OCF VS FCFORP.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B -2B -3B -4B

1.2 Ratios

ORP has a better Return On Assets (9.74%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 71.82%, ORP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 9.74%
ROE 71.82%
ROIC N/A
ROA(3y)-5.89%
ROA(5y)-3.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ORP.PA Yearly ROA, ROE, ROICORP.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 100 150 200 250

1.3 Margins

Looking at the Profit Margin, with a value of 26.07%, ORP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of ORP has grown nicely.
The Operating Margin and Gross Margin are not available for ORP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 26.07%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y85.55%
PM growth 5Y32.24%
GM growth 3YN/A
GM growth 5YN/A
ORP.PA Yearly Profit, Operating, Gross MarginsORP.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

1

2. Health

2.1 Basic Checks

ORP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORP has been reduced compared to 1 year ago.
The number of shares outstanding for ORP has been reduced compared to 5 years ago.
ORP has a better debt/assets ratio than last year.
ORP.PA Yearly Shares OutstandingORP.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B
ORP.PA Yearly Total Debt VS Total AssetsORP.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

ORP has an Altman-Z score of 0.39. This is a bad value and indicates that ORP is not financially healthy and even has some risk of bankruptcy.
ORP has a worse Altman-Z score (0.39) than 85.71% of its industry peers.
ORP has a Debt/Equity ratio of 4.30. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ORP (4.30) is worse than 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.3
Debt/FCF N/A
Altman-Z 0.39
ROIC/WACCN/A
WACC5.23%
ORP.PA Yearly LT Debt VS Equity VS FCFORP.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2B 4B 6B 8B

2.3 Liquidity

ORP has a Current Ratio of 0.60. This is a bad value and indicates that ORP is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.60, ORP is doing worse than 85.71% of the companies in the same industry.
A Quick Ratio of 0.60 indicates that ORP may have some problems paying its short term obligations.
ORP has a worse Quick ratio (0.60) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.6
Quick Ratio 0.6
ORP.PA Yearly Current Assets VS Current LiabilitesORP.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

8

3. Growth

3.1 Past

ORP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 360.39%, which is quite impressive.
ORP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 116.08% yearly.
Looking at the last year, ORP shows a quite strong growth in Revenue. The Revenue has grown by 11.04% in the last year.
The Revenue has been growing by 8.73% on average over the past years. This is quite good.
EPS 1Y (TTM)360.39%
EPS 3Y301.6%
EPS 5Y116.08%
EPS Q2Q%278.1%
Revenue 1Y (TTM)11.04%
Revenue growth 3Y9.84%
Revenue growth 5Y8.73%
Sales Q2Q%11.4%

3.2 Future

Based on estimates for the next years, ORP will show a very strong growth in Earnings Per Share. The EPS will grow by 26.14% on average per year.
The Revenue is expected to grow by 8.11% on average over the next years. This is quite good.
EPS Next Y99.7%
EPS Next 2Y41.51%
EPS Next 3Y26.14%
EPS Next 5YN/A
Revenue Next Year6.41%
Revenue Next 2Y9.12%
Revenue Next 3Y8.11%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ORP.PA Yearly Revenue VS EstimatesORP.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
ORP.PA Yearly EPS VS EstimatesORP.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 100 -100 200

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 1.20, which indicates a rather cheap valuation of ORP.
Compared to the rest of the industry, the Price/Earnings ratio of ORP indicates a rather cheap valuation: ORP is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ORP to the average of the S&P500 Index (26.59), we can say ORP is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for ORP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.2
Fwd PE N/A
ORP.PA Price Earnings VS Forward Price EarningsORP.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 -30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORP.PA Per share dataORP.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ORP's earnings are expected to grow with 26.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)0.01
EPS Next 2Y41.51%
EPS Next 3Y26.14%

0

5. Dividend

5.1 Amount

No dividends for ORP!.
Industry RankSector Rank
Dividend Yield N/A

EMEIS SA

EPA:ORP (7/2/2024, 5:28:19 PM)

12.465

+0.15 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-14 2024-05-14
Earnings (Next)07-24 2024-07-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.98B
Analysts48.89
Price Target170.74 (1269.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)98.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE 1.2
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF 5.42
P/B 1.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)10.36
EY83.11%
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)2.3
OCFY18.45%
SpS32.65
BVpS11.85
TBVpS-6.36
PEG (NY)0.01
PEG (5Y)0.01
Profitability
Industry RankSector Rank
ROA 9.74%
ROE 71.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 26.07%
GM N/A
FCFM N/A
ROA(3y)-5.89%
ROA(5y)-3.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y85.55%
PM growth 5Y32.24%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 4.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.6
Quick Ratio 0.6
Altman-Z 0.39
F-Score6
WACC5.23%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)13.91%
Cap/Sales(5y)16.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)360.39%
EPS 3Y301.6%
EPS 5Y116.08%
EPS Q2Q%278.1%
EPS Next Y99.7%
EPS Next 2Y41.51%
EPS Next 3Y26.14%
EPS Next 5YN/A
Revenue 1Y (TTM)11.04%
Revenue growth 3Y9.84%
Revenue growth 5Y8.73%
Sales Q2Q%11.4%
Revenue Next Year6.41%
Revenue Next 2Y9.12%
Revenue Next 3Y8.11%
Revenue Next 5YN/A
EBIT growth 1Y81.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year127.08%
EBIT Next 3Y32.13%
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.64%
OCF growth 3Y-22.21%
OCF growth 5Y-2.48%